Pfizer Inc.
PFE
Kedudukan dalam Saham
#119
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Harga Saham
$29.47
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$167.94B
Perubahan (1 hari)
-0.27%
Perubahan (1 tahun)
19.34%
Negara
US
Perdagangan Pfizer Inc. (PFE)
Kategori
Healthcare
Nisbah P/E bagi Pfizer Inc. (PFE)
Nisbah P/E pada October 2026 TTM: 38.60
Menurut laporan kewangan dan harga saham terkini Pfizer Inc., nisbah P/E semasa (TTM) ialah 38.60. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 18.74.
Sejarah nisbah P/E bagi Pfizer Inc. dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 38.60 | 111.95% |
| 2025 | 18.21 | -2.80% |
| 2024 | 18.74 | -75.40% |
| 2023 | 76.17 | 731.36% |
| 2022 | 9.16 | -38.65% |
| 2021 | 14.93 | -33.11% |
| 2020 | 22.33 | 75.65% |
| 2019 | 12.71 | -41.66% |
| 2018 | 21.79 | 126.47% |
| 2017 | 9.62 | -62.98% |
| 2016 | 25.98 | -4.22% |
| 2015 | 27.13 | 31.45% |
| 2014 | 20.64 | 21.52% |
| 2013 | 16.98 | -6.03% |
| 2012 | 18.07 | -1.86% |
| 2011 | 18.42 | 14.15% |
| 2010 | 16.13 | 15.33% |
| 2009 | 13.99 | -0.61% |
| 2008 | 14.08 | -22.47% |
| 2007 | 18.16 | 12.58% |
| 2006 | 16.13 | -24.59% |
| 2005 | 21.39 | 26.25% |
| 2004 | 16.94 | -72.58% |
| 2003 | 61.78 | 216.04% |
| 2002 | 19.55 | -35.41% |
| 2001 | 30.27 | -58.36% |
| 2000 | 72.68 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 40.53 | 5.01% |
US
|
|
| 38.50 | -0.26% |
US
|
|
| 79.88 | 106.95% |
US
|
|
| 116.96 | 203.02% |
US
|
|
| 22.25 | -42.36% |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.